RxDoctor Payments Data

Marc Schumer, MD

Urology · Amityville, NYNPI 1407819691

Payments from drug & device makers

$10,507in general payments, 2019–2025

Across 59 payments — averaging $178.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • Avyxa Pharma, LLC$4K
  • AstraZeneca$930
  • Astellas Pharma US Inc$343
  • Ferring Pharmaceuticals Inc.$215
  • Immunitybio, Inc.$162
  • plus $577 from 14 others

What the payments were for

  • Consulting fees$4,23040%
  • Speaking & faculty fees$2,00019%
  • Travel & lodging$2,18421%
  • Food & beverage$1,98719%
  • Education$1061%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)13$4,163
Avyxa Pharma, LLC8$4,118
AstraZeneca1$930
Astellas Pharma US Inc11$343
Ferring Pharmaceuticals Inc.4$215
Immunitybio, Inc.1$162
Medtronic1$144
Teleflex LLC1$82
Dendreon Pharmaceuticals LLC3$66
Pfizer4$64
Bayer2$47
Tolmar Pharmaceuticals, Inc.2$41
Coloplast1$23
Travere Therapeutics, Inc.1$22
180 Medical, Inc.1$19
Clarus Therapeutics Inc.1$15
AbbVie1$14
Rochester Medical Corporation1$14
Olympus America Inc.1$13
Hollister Incorporated1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,507 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$444,613
Medicare patients
787
Services billed
7,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide13$206,671
MyrbetriqMirabegron33$39,009
GemtesaVibegron27$35,778
Tamsulosin Hcl1,000$19,088
Silodosin85$8,738
Methenamine Hippurate119$8,023
Oxybutynin Chloride ErOxybutynin Chloride270$7,369
Dutasteride81$3,605
CefuroximeCefuroxime Axetil198$2,536
Finasteride155$2,243
Potassium Citrate ErPotassium Citrate19$1,970
Testosterone20$1,916
NitrofurantoinNitrofurantoin Macrocrystal47$1,867
Alfuzosin Hcl ErAlfuzosin Hcl72$1,282
Cephalexin102$1,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$343$245,68046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.

Other urology in Amityville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →